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ABSTRACT
Resistance to chemotherapy substantially hinders successful glioblastoma (GBM) 
treatment, contributing to an almost 100% mortality rate. Resistance to the frontline 
chemotherapy, temozolomide (TMZ), arises from numerous signaling pathways that 
are deregulated in GBM, including Hedgehog (Hh) signaling. Here, we investigate 
suppression of Hh signaling as an adjuvant to TMZ using U87-MG and T98G cell lines 
as in vitro models of GBM. We found that silencing GLI1 with siRNA reduces cell 
metabolic activity by up to 30% in combination with TMZ and reduces multidrug 
efflux activity by 2.5-fold. Additionally, pharmacological GLI inhibition modulates 
nuclear p53 levels and decreases MGMT expression in combination with TMZ. While 
we surprisingly found that silencing GLI1 does not induce apoptosis in the absence of 
TMZ co-treatment, we discovered silencing GLI1 without TMZ co-treatment induces 
senescence as evidenced by a significant 2.3-fold increase in senescence associated 
β-galactosidase staining, and this occurs in a loss of PTEN-dependent manner. Finally, 
we show that GLI inhibition increases apoptosis in glioma stem-like cells by up to 6.8-
fold in combination with TMZ, and this reduces the size and number of neurospheres 
grown from glioma stem-like cells. In aggregate, our data warrant the continued 
investigation of Hh pathway inhibitors as adjuvants to TMZ chemotherapy and 
highlight the importance of identifying signaling pathways that determine whether 
co-treatment will be successful.
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 43), pp: 27000-27015
INTRODUCTION
Glioblastoma (GBM) is the deadliest form of 
brain cancer and represents the most common central 
nervous system tumor in adults, accounting for 45.6% 
of all malignant primary brain tumors [1]. Standard 
treatment for newly diagnosed primary GBM includes 
surgical resection, radiation, and chemotherapy [2, 3]. 
Temozolomide (TMZ) is the current frontline 
chemotherapeutic for GBM and acts as an alkylating 
agent to induce DNA damage and trigger cell death. 
While the addition of TMZ chemotherapy to the 
standard radiotherapy has increased median patient 
survival time from 12.1 months to 14.6 months, tumor 
recurrence remains virtually inevitable, and nearly 100% 
of patients ultimately succumb to disease [4]. GBM 
recurrence is driven in large part by intrinsic or acquired 
chemoresistance [5], and tumors that have recurred often 
demonstrate enhanced resistance to chemotherapy and are 
more invasive than the primary lesion [2].
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GBM drug resistance is mediated both by signaling 
mechanisms throughout the tumor and by an aggressive 
subpopulation of tumor cells known as glioma stem-like 
cells, or GSCs. In both GSCs and differentiated GBM cells, 
deregulated DNA damage repair mechanisms oppose TMZ-
mediated cytotoxicity by repairing DNA damage caused by 
TMZ to prevent apoptosis [6, 7]. In particular, upregulated 
MGMT, an enzyme that removes alkyl groups transferred 
to DNA by TMZ, is a known prognostic indicator of poor 
response to TMZ [8]. Additionally, mutations to the p53/
Mdm2/PTEN tumor suppressor axis promote cell cycle 
progression to suppress TMZ-induced apoptosis [9, 10]. 
Further, upregulation of EGFR signaling through wild-
type EGFR and the commonly expressed EGFRvIII 
mutant stimulate survival signaling through the Ras/Raf/
MAPK and PI3k/Akt/mTOR pathways to promote TMZ 
resistance [11, 12]. In parallel, TMZ resistance is provided 
by a subpopulation of multipotent, slow-cycling GSCs 
that evade chemotherapeutic apoptosis and repopulate the 
tumor with resistant cells following treatment [13–15]. 
While much remains unknown regarding their biology, 
these cells may be identified by various markers (CD133, 
CD44, nestin, ALDH1, Oct4, Sox2), and differential 
expression of these markers suggest a stemness hierarchy 
that may correlate with aggressiveness [16]. Elimination 
of GSCs remains a barrier to complete tumor eradication.
A growing body of evidence attributes tumor 
resistance phenotypes and the maintenance of GSCs 
to deregulated developmental pathways, such as 
Notch, Wnt, and Hedgehog (Hh) signaling [17–21]. In 
particular, research has demonstrated that while several 
developmental pathways contribute to GBM progression, 
Hh signaling is indispensable for GSC proliferation and 
tumorigenesis [19] and may be an impactful target for 
new GBM treatment strategies. Hh signaling is a highly 
conserved developmental pathway that is normally 
minimally active in differentiated adult tissue, but also 
plays an impactful role in the progression and maintenance 
of several cancers, including GBM. Hh signaling is 
activated when Hh ligands, most notably sonic hedgehog 
(Shh), bind the extracellular domain of the Patched (Ptc) 
transmembrane receptor. Ptc then relieves its suppression 
of Smoothened (Smo), a second transmembrane protein, 
which in turn initiates an intracellular signaling cascade 
that translocates members of the GLI family of zinc 
finger transcription factors to the nucleus to regulate the 
expression of target genes (Supplementary Figure 1). 
Within this family of transcription factors, upregulated 
GLI1 expression and transcriptional activity is associated 
with poor patient prognosis in several cancers [22]. 
Further, GLI1 is known to regulate proliferation and cell 
cycle progression [23, 24], cell survival [24, 25], migration 
and invasion [26], cancer cell stemness and self-renewal 
[23], and response to chemotherapy [18, 23, 27]. 
In this study, we investigated the role of Hh/GLI1 
signaling in GBM resistance to TMZ. Specifically, we 
evaluated the molecular and phenotypic consequences of 
GLI1 inhibition as an adjuvant to TMZ treatment to assess 
the therapeutic potential of this co-treatment strategy. In 
this work, we used U87-MG and T98G cells as established 
in vitro models of GBM. These models were chosen 
because they both exhibit active Hh signaling as indicated 
by GLI1 expression and nuclear localization, but they 
differ in the expression of known molecular contributors 
to TMZ resistance. For example, U87-MG cells express 
wild-type p53, while T98G cells express a mutant p53 
variant [9]. Although the role of p53 variants in GBM are 
not fully understood, evidence suggests that wild-type 
p53 generally retains tumor suppressive functions, while 
mutant p53 may promote tumor progression [9, 28, 29]. 
Additionally, T98G cells, but not U87-MG cells, express 
high levels of MGMT, which is a primary mechanism 
by which GBM cells resist alkylating chemotherapies 
[9, 30, 31]. Because MGMT contains a GLI1 binding 
domain and consequently may be regulated by Hh 
signaling [32], MGMT expression may influence GBM 
cell response to co-treatment with Hh/GLI1 inhibitors and 
TMZ. Thus, we aimed to capture these key phenotypic 
differences characteristic of GBM resistance mechanisms 
with our choice of established cell models.
Here, we show that silencing GLI1 prior to treating 
cells with TMZ increases the cytotoxicity of TMZ against 
GBM cells. We provide additional evidence that silencing 
GLI1 expression reduces the proliferation of U87-MG 
and T98G cells to abrogate disease progression. We also 
demonstrate that silencing GLI1 promotes sensitivity to 
TMZ by broadly reducing efflux behavior attributed to 
multidrug transporters. Further, we show that Hh pathway 
inhibition induces the expression of wild-type, but not 
mutant p53, suggesting that silencing GLI1 may induce 
tumor suppression via a p53-dependent mechanism. We 
initially hypothesized that GLI1 silencing without TMZ 
co-treatment would induce apoptosis via p53, however, 
we observed activation of separate tumor suppressive 
pathway. Specifically, we found that silencing GLI1 
induces senescence rather than apoptosis, and this occurs 
via a mechanism that depends on the absence of PTEN. 
Finally, we demonstrate that combined Hh/GLI1 inhibition 
and TMZ treatment induces apoptosis and suppresses 
the growth of U87-MG cells cultured as neurospheres, 
suggesting an abrogation of glioma stem cell-like 
behavior. In aggregate, this data warrants the continued 
investigation of Hh-targeted therapies as adjuvants for 
GBM management.
RESULTS
U87-MG and T98G GBM cells exhibit active Hh 
signaling required for proliferation
In initial studies, we aimed to validate that both 
U87-MG and T98G cells exhibit active Hh signaling, 
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making them suitable in vitro GBM models for this work. 
Nuclear localization of GLI1 was taken to indicate Hh 
pathway activation, as active Hh signaling produces GLI1 
transcriptional activity and cytoplasmic GLI1 undergoes 
proteasomal degradation [33]. U87-MG and T98G cells 
were treated with recombinant human Shh (rhShh) 
for 48 hours and assessed for GLI1 expression using 
immunofluorescence. Images obtained using fluorescence 
microscopy reveal that GLI1 is present in both the nucleus 
and cytoplasm of untreated U87-MG and T98G cells, 
suggesting that Hh signaling is active in both cell lines. 
Further, stimulation with rhShh increases U87-MG GLI1 
staining intensity by ~30% in the nucleus and ~40% in 
the cytoplasm (Figure 1A, 1C). In contrast, GLI1 staining 
intensity is conserved with rhShh treatment in T98G cells 
(Figure 1B, 1C), indicating that pathway activity is already 
maximal in untreated culture, that GLI1 is primarily 
regulated by other Hh ligands (Indian, Desert hedgehog), 
or by noncanonical signaling mechanisms in these cells.
GLI1 is well understood to positively regulate cell 
proliferation through direct transcriptional upregulation 
of cyclinD/E, Rb tumor suppressor inhibitors, c-Myc, 
and other pro-proliferative genes [34–36]. Therefore, we 
hypothesized that silencing GLI1 should decrease the 
proliferation of both U87-MG and T98G cells. To test 
this, U87-MG and T98G cells were transiently transfected 
with siRNA against GLI1 (siGLI1) or a scrambled control 
siRNA (siScr) and subsequently analyzed by an EdU 
incorporation assay. Flow cytometric analysis revealed 
that silencing GLI1 decreased the fraction of proliferating, 
EdU+ U87-MG cells by ~60% and the fraction of 
EdU+ T98G cells by ~44% (Figure 1D, Supplementary 
Figure 2). These results further support the presence of Hh 
pathway activity in U87-MG and T98G cells even without 
stimulation with exogenous rhShh.
Silencing GLI1 potentiates GBM cell response to 
TMZ by decreasing multidrug efflux activity
Having established that Hh signaling is active 
in both of our GBM cell models and contributes to 
cell proliferation, we asked whether Hh/GLI1 activity 
contributes to cellular resistance to TMZ. To test this, 
U87-MG and T98G cells were transiently transfected 
Figure 1: U87-MG and T98G GBM cells exhibit active Hh signaling via GLI1. rhShh increases GLI1 expression and nuclear 
translocation in (A) U87-MG but not (B) T98G GBM cells by immunofluorescence. Scale bars = 100 µm. (C) Quantitative image analysis 
reveals that U87-MG GLI1 intensity is significantly increased by ~30% in the nucleus and by ~40% in the cytoplasm relative to that in 
control cells. Data are shown as mean ± standard deviation from 3 independent experiments, *p < 0.05 by Student’s t-test relative to control. 
Changes in T98G GLI1 intensity are insignificant. # no significance by Student’s t-test. (D) By EdU incorporation and flow cytometry 
analysis, silencing GLI1 decreases the proliferation of U87-MG and T98G cells by ~60% and ~44%, respectively, relative to siScr. Data 
are shown as mean ± standard deviation, *p = 0.03, **p = 0.002 by paired t-test relative to control.
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with siRNA targeting GLI1 (siGLI1) or a scrambled 
control (siScr), then treated with a range of TMZ doses 
(0–1500 µM). Treatment efficacy was evaluated using an 
AlamarBlue assay to measure cellular metabolic activity. 
In U87-MG cells, we found that silencing GLI1 prior to 
TMZ treatment decreases metabolic activity up to 30% 
for TMZ doses through 1000 µM, past which we no 
longer observed increased efficacy with co-treatment 
(Figure 2A). We further conducted simple analysis to 
determine whether the treatments employed in tandem 
were synergistic, additive, or antagonistic. Briefly, the 
projected additive effect was calculated by multiplying 
the metabolic activity fraction for each treatment 
(siGLI1 or TMZ) individually. If the measured effect was 
greater than the projected additive, the co-treatment was 
considered synergistic. Conversely, if the measured effect 
was less than the projected additive, the co-treatment was 
considered antagonistic. Using this analysis method, we 
found that co-treating U87-MG cells with siGLI1 and 
TMZ produces an additive decrease in metabolic activity 
for all TMZ doses tested (Supplementary Figure 3). In 
T98G cells, while silencing GLI1 alone significantly 
reduced metabolic activity, co-treatment with TMZ 
induced an additive therapeutic effect at 250 µM TMZ, 
and an antagonistic therapeutic effect was exerted at 
higher TMZ doses (Figure 2A, Supplementary Figure 3). 
These results suggest that additional signaling mechanisms 
are important for regulating GBM cell response to TMZ, 
especially in T98G cells, but support that Hh inhibitors 
may improve the anticancer efficacy of low TMZ doses.
We further sought to delineate mechanisms by 
which silencing GLI1 may improve GBM cell TMZ 
response. Previous research has demonstrated that GLI1 
transcriptionally regulates several transmembrane efflux 
transporters, such as MDR1/ABCB1, MRP1, LRP, and 
BCRP/ABCG2, which mediate chemotherapy resistance 
in several cancers [27, 37, 38]. Therefore, we asked 
whether silencing GLI1 could translate to a net reduction 
in GBM cell multidrug efflux activity. To test this, we used 
a dye-based efflux activity assay in which intracellular 
rhodamine intensity is taken to indicate small molecule 
retention. Rhodamine123 is a suitable dye choice for these 
experiments because it is a known substrate for multidrug 
efflux transporters [39]. In these experiments, U87-MG 
and T98G cells were transiently transfected with siGLI1 or 
siScr, then incubated with Rhodamine123 for 20 minutes. 
The dye was removed and cells were further incubated 
in fresh media for an additional 20 minutes. Cells were 
then trypsinized and analyzed for Rhodamine123 
intensity by flow cytometry. Flow cytometry analysis 
reveals that silencing GLI1 can increase the intracellular 
Rhodamine123 intensity by 2.5-fold in U87-MG cells 
and 1.5-fold in T98G cells (Figure 2B, 2C). Therefore, 
we conclude that silencing GLI1 can reduce multidrug 
efflux activity to improve the retention of small molecule 
chemotherapeutics.
Figure 2: Silencing GLI1 influences GBM cell response to TMZ and reduces multidrug efflux activity. (A) By AlamarBlue 
assay, U87-MG and T98G metabolic activity is significantly decreased with combined GLI1 silencing and low-dose TMZ treatment. Data 
are shown as mean ± standard deviation, *p < 0.01 by one-way ANOVA with post-hoc Tukey. (B) Silencing GLI1 reduces multidrug 
efflux activity in both U87-MG and T98G cells. Flow cytometry reveals that silencing GLI1 prior to incubating cells with Rhodamine123 
increases cellular Rhodamine123 intensity by 2.5-fold and 1.5-fold in U87-MG and T98G cells, respectively (C). Data are shown as mean 
± standard deviation, *p = 0.0008, #p = 0.07 by paired t-test relative to siScr.
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Suppressing Hh signaling modulates p53 and 
MGMT expression in GBM cells
Next, we asked whether Hh pathway inhibition 
could restore tumor suppressive activity in GBM cells. 
To evaluate tumor suppressive activity in U87-MG and 
T98G cells, we used immunofluorescent staining to assess 
the relative expression and localization of p53. Wild-type 
p53 transcriptionally regulates multiple genes involved in 
apoptosis, cell cycle arrest, DNA repair, and senescence in 
response to DNA damage such as that induced by hypoxia, 
radiation, or chemotherapy [28]. Thus, upregulation of 
wild-type p53 should induce tumor suppressive functions 
to mediate GBM cell death in response to chemotherapy. 
The role of mutant p53 in GBM is more poorly understood, 
and mutant p53 may promote both tumor suppressive and 
tumorigenic cell signaling. Both wild-type and mutant p53 
are represented in this study, where U87-MG cells express 
wild-type p53 and T98G cells express a mutant p53 
variant [9]. Cells seeded on coverslips were treated with 
the pharmacological GLI inhibitor GANT61 [40] for 48 
hours, then stained for p53 and analyzed by quantitative 
fluorescence microscopy. We demonstrate that GANT61 
significantly increases nuclear p53 by 43.4% in U87-MG 
cells (Figure 3A, 3C) and decreases nuclear p53 by 21.5% 
in T98G cells (Figure 3B, 3C).
We further investigated the potential role of MGMT 
in T98G resistance to TMZ, since MGMT is expressed 
highly in T98G cells. One previous study investigating 
other GBM cell lines reported that MGMT can be up-
regulated in response to TMZ [7], so we asked whether 
TMZ-mediated upregulation of MGMT could be 
driving TMZ resistance in T98G cells. T98G cells were 
transfected with siGLI1 or siScr and subsequently treated 
with 250–500 µM TMZ for 48 hours, then lysed and 
assessed for MGMT expression by Western blotting. Our 
results show that MGMT expression is reduced in T98G 
cells treated with TMZ in a dose-dependent manner, and 
this MGMT downregulation may be enhanced when TMZ 
is combined with siGLI1 (Figure 3D). Accordingly, other 
mechanisms may be predominantly responsible for T98G 
TMZ resistance under Hh pathway inhibition.
Silencing GLI1 does not induce apoptosis in 
GBM cells without TMZ co-treatment
Because Hh pathway suppression increased wt-
p53 in U87-MG cells and decreased mut-p53 in T98G 
cells, we hypothesized that silencing GLI1 might induce 
apoptosis in GBM cells even in the absence of TMZ co-
treatment. To test this, we first evaluated the expression of 
proteins downstream of p53 that might be upregulated in 
Figure 3: Hh inhibitors modulate p53 and MGMT expression in GBM cells. Nuclear p53 staining intensity increases with 
GANT61-mediated Hh inhibition in (A, C) U87-MG cells by 43.4%, but decreases in (B, C) T98G cells by 21.5% relative to that in control 
cells. Data are shown as mean ± standard deviation from 3 independent experiments, *p < 0.005 by Student’s t-test. Scale bars = 50 µm. 
(D) By Western blotting, T98G MGMT expression decreases in a TMZ-dependent manner. TMZ-induced downregulation of MGMT may 
be potentiated by GLI1 silencing.
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p53-mediated apoptosis. Contrary to our expectation, in 
U87-MG cells treated with siGLI1, we observed decreases 
in Rb, p21, Bid, and MDM2 expression (Figure 4A). In 
T98G cells, we observed slight increases in PTEN and 
PUMA expression and decreases in Rb, Fas, Bid, and 
MDM2 expression by Western blotting (Figure  4A). 
To validate these surprising results and ensure that 
p53-mediated apoptosis was not occurring by another 
signaling mechanism, we used AnnexinV-FITC/PI 
staining to directly assess apoptosis in cells treated under 
identical conditions. Surprisingly, we observed a slight 
but insignificant increase in the fraction of apoptotic cells 
(AnnexinV+, PI±) following GLI1 silencing, with 14 ± 
3.6 % of cells treated with siGLI1 staining AnnexinV+ 
versus 9.9 ± 0.9% of cells treated with siScr (Figure 4B). 
Therefore, we concluded that direct induction of apoptosis 
by a p53-dependent mechanism is unlikely to cause 
the previously observed decreases in proliferation and 
metabolic activity with GLI1 silencing.
Silencing GLI1 induces senescence in GBM cells 
in a manner dependent on the absence of PTEN 
Our studies produced the surprising result that 
although silencing GLI1 reduces GBM cellular metabolic 
activity alone and in combination with TMZ and 
modulates p53 expression, this does not significantly 
induce apoptosis in the absence of TMZ co-treatment. 
Therefore, we asked whether we could be observing 
senescence rather than apoptosis in response to siGLI1 
alone. To test this, we used senescence associated 
β-galactosidase (SAβGal) staining to identify senescent 
cells following GLI1 silencing. We observed a marked 
increase in SAβGal staining (Figure 5A) in U87-
MG cells treated with siGLI1, but not in T98G cells. 
Interestingly, previous research has identified that loss 
of PTEN can induce premature senescence, which may 
have a compensatory role for apoptosis in this context 
[41]. Because U87-MG cells exhibit loss of PTEN while 
T98G cells do not (Figure 4A), we hypothesized that loss 
of PTEN might explain the observed senescent phenotype 
in response to siGLI1. Indeed, we observed that inducing 
PTEN expression reversed this behavior; co-transfecting 
U87-MG cells with siGLI1 and a control plasmid (pHA) 
significantly increased SAβGal staining by 2.3-fold 
relative to cells co-transfected with siScr and pHA, while 
co-transfection with siGLI1 and pPTEN reversed this 
phenotype (Figure 5B, 5C). Therefore, we concluded that 
silencing GLI1 induces senescence in a manner dependent 
on the absence of PTEN.
Figure 4: Silencing GLI1 does not correlate with apoptosis in GBM cells. (A) By Western blotting, proteins associated with 
apoptosis induction do not increase with GLI1 silencing. (B) GLI1 silencing does not significantly increase AnnexinV-FITC/PI staining, # 
no significant difference in the fraction of viable, early apoptotic, late apoptotic, or necrotic cells by one-way ANOVA with posthoc Tukey. 
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Hh inhibition and TMZ co-treatment promotes 
apoptosis in neurospheres and impairs 
neurosphere growth
Having established that Hh inhibition induces 
senescence in a loss of PTEN-dependent manner as a 
standalone therapy, we were interested in the fate of GSCs 
co-treated with Hh inhibitors and TMZ. To model this, we 
used an in vitro model of neurosphere formation in which 
neurospheres were grown from a single cell suspension 
in serum-free, chemically-defined medium. Importantly, 
GBM cells grown as neurospheres are more sensitive to 
clinically-relevant TMZ doses than GBM cells grown in 
adherent culture [42], so we anticipated that neurospheres 
would be a more appropriate model to elucidate the effects 
of Hh inhibition and TMZ co-treatment. We validated 
that U87-MG cells grown as neurospheres are more 
stem-like than adherent cells using qPCR to measure 
changes in the expression of genes associated with this 
phenotype (Supplementary Figure 4). We found that U87-
MG neurospheres exhibit a 10-fold increase in CD133 
expression and a 5-fold increase in Nanog expression 
(Supplementary Figure 4). Next, we investigated the extent 
of apoptosis induced in U87-MG GBM neurospheres by 
co-treatment with GANT61 and TMZ using AnnexinV/
PI staining. We found that, as a monotherapy, only the 
highest tested GANT61 dose (15 µM) is sufficient to 
induce a significant increase in apoptotic (AnnexinV+, 
PI±) cells relative to untreated controls (Figure 6A, 6B, 
Supplementary Figure 5), which increased the fraction 
of apoptotic cells to 41%. While TMZ alone induces 
apoptosis in 54% of cells, the addition of 10 or 15 µM 
GANT61 significantly increases the fraction of apoptotic 
(AnnexinV+, PI±) cells to 83% or 93%, respectively 
(Figure 6A, 6B, Supplementary Figure 5). Further, synergy 
analysis using the previously described method revealed 
that co-treating U87-MG neurospheres with TMZ and 10 
or 15 µM GANT61 produced a statistically significant 
synergistic decrease in the fraction of viable (AnnexinV-, 
PI-) cells (Supplementary Figure 6). This data supports the 
hypothesis that co-treatment with TMZ and GANT61 may 
cooperatively promote apoptosis in GBM neurospheres. 
We next investigated the consequences of GANT61/
TMZ-mediated apoptosis on neurosphere growth. Using 
brightfield microscopy, we observed a striking decrease in 
neurosphere size induced by GANT61/TMZ co-treatment 
and correlating with increased doses of GANT61 (Figure 
6C, 6D; Supplementary Figure 7). Quantitative image 
analysis also revealed that GANT61 significantly reduced 
the number of neurospheres formed with or without co-
treatment with TMZ (Figure 6D).
DISCUSSION
In this study, we evaluated the therapeutic potential 
of Hh pathway inhibition as an adjuvant to TMZ 
chemotherapy using in vitro models of GBM. Through this 
work, we sought to identify key molecular and phenotypic 
changes that occur in GBM cells because of co-treatment 
with Hh pathway inhibitors and TMZ. We found that 
silencing GLI1 before administering TMZ to GBM cells 
enhanced the cytotoxic effects of chemotherapy, and this 
Figure 5: Silencing GLI1 induces senescence in U87-MG cells in a manner dependent on the absence of PTEN. (A) 
SAβGal staining (teal) demonstrates that silencing GLI1 induces senescence in U87-MG cells. (C) Quantitative image analysis across 
three independent experiments confirms that (B) PTEN expression reverses siGLI1-induced senescence, *p < .05 by one-way ANOVA 
with post-hoc Tukey test.
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Figure 6: Hh inhibitors and TMZ cooperatively promote apoptosis in U87-MG neurospheres and suppress neurosphere 
growth. (A) Flow cytometric scatterplots displaying AnnexinV-FITC and PI staining intensities in U87-MG cells grown as neurospheres 
in medium containing GANT61 (0 or 10 µM) and TMZ (0 or 50 µM TMZ) from one representative experiment. (B) The fraction of 
apoptotic (AnnexinV+) U87-MG cells grown as neurospheres in medium containing GANT61 and TMZ (50 µM TMZ), summarized 
across 3 independent experiments. Data shown are means ± standard deviation from 3 independent experiments, *p < 0.05, **p < 0.01 by 
one-way ANOVA with post-hoc Fisher’s least significant difference test. (C) Representative brightfield images of U87-MG neurospheres 
grown for one week in medium containing GANT61 and TMZ (10 µM TMZ). Scale bar = 500 µm. (D) (Left) Number of spheres counted 
by automated image analysis, averaged across 9 independent replicates. Data shown are means ± standard deviation from 9 independent 
experiments, *p < 0.05, **p < 0.01 by one-way ANOVA with post-hoc Tukey test. (Right) Sphere size (projected area) as determined by 
automated image analysis from one representative experiment.
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effect is likely dependent on the status of additional GBM-
promoting genes. Further, this enhanced TMZ cytotoxicity 
correlated with a decrease in multidrug efflux activity and 
an increase in wild-type p53, a key mediator of apoptosis, 
cell cycle arrest, and senescence [28]. Interestingly, the 
increase in p53 observed in U87-MG cells did not induce 
apoptosis, but instead triggered senescence in a manner 
dependent on the loss of PTEN expression. Finally, 
we found that co-treating GBM cells in neurosphere 
culture with Hh pathway inhibitors and TMZ promotes 
apoptosis and reduces neurosphere formation, suggesting 
an inhibition of glioma stem cell-like behavior. Overall, 
this work provides evidence that Hh pathway inhibition 
may overcome cellular mechanisms that promote TMZ 
resistance, and the data warrant continued investigation of 
this combination treatment.
Previous research has demonstrated that Hh 
inhibition through gene regulatory or pharmacological 
means can sensitize GBM cells to TMZ [18, 23, 43] and 
has suggested a number of possible mechanisms to support 
these findings. Although many researchers either do not 
observe MGMT expression in U87-MG cells [9, 30, 31] or 
observe very little MGMT expression [44, 45], one study 
reported that GANT61-mediated Hh pathway suppression 
improved TMZ sensitivity by repressing MGMT and 
Notch proteins in U87 and U251 cells [43]. Consistently, 
another investigation reported that targeting both Hh and 
Notch signaling could further improve TMZ sensitivity 
in GBM cells [18]. In the present study, we demonstrate 
that silencing GLI1 prior to TMZ treatment can additively 
improve chemotherapeutic efficacy in U87-MG cells 
cultured in adherent conditions (Figure 2A). Notably, 
U87-MG cells are highly refractory to TMZ treatment 
in adherent culture. This is evident in that minimal U87-
MG toxicity is observed for TMZ doses up to 500 µM, 
approximately 10-fold higher than the maximum clinically 
feasible TMZ dose [46]. Accordingly, it is encouraging 
that the therapeutic benefit afforded by co-treatment was 
most prominent for lower TMZ doses, suggesting that 
the combination of Hh inhibitors and low-dose TMZ 
may improve treatment outcomes while mitigating off-
target toxicity. We can extend these findings to U87-MG 
cells grown in neurosphere culture, thought to be more 
representative of a GSC-rich population. Interestingly, we 
observed a synergistic, or greater than additive, therapeutic 
effect induced by co-treatment with GANT61 and TMZ in 
these models (Figure 6A, 6B, Supplementary Figure 6). We 
suspect this is because Hh signaling is upregulated in GSCs 
relative to differentiated GBM cells [18], and neurospheres 
may consequently be more sensitive to its suppression. 
Additionally, some GBM cell lines grown as neurospheres 
exhibit greater sensitivity to chemotherapeutic agents 
including carmustine and TMZ than GBM cell lines grown 
in adherent culture [42]. Surprisingly, and in contrast to 
our observations in U87-MG cells, our studies show that 
silencing GLI1 prior to treating T98G cells with TMZ 
chemotherapy at doses greater than 250 µM produced an 
antagonistic therapeutic effect (Figure 2A, Supplementary 
Figure 3). Though we initially hypothesized that this could 
be due to MGMT upregulation, we found that siGLI1/
TMZ co-treatment decreases MGMT expression at TMZ 
doses greater than 250 µM (Figure 3D), and we concluded 
that other mechanisms are responsible for this antagonistic 
therapeutic effect. We speculate that this may occur because 
silencing GLI1 may relieve GLI1-mediated suppression of 
mutant p53, which can oppose TMZ cytotoxicity [10, 28]. 
These studies warrant future investigation to delineate the 
cause of this differential drug response. 
Further, Hh signaling has been linked to the 
upregulation of drug efflux transporters that reduce 
the intracellular concentration of small molecule 
chemotherapeutics, rendering them ineffective and 
imparting drug resistance [27, 37, 38, 47]. While several 
investigations have shown that Hh inhibition decreases 
the expression of one or more such transporters at the 
protein level, we demonstrate here that silencing GLI1 
does produce a net decrease in multidrug efflux activity. 
In these studies, we used Rhodamine123 as a tracer dye 
to indicate efflux activity, as Rhodamine123 is a known 
substrate for such transporters. Our data show that 
silencing GLI1 prior to incubating U87-MG cells with 
Rhodamine123 can significantly improve intracellular 
dye intensity, and therefore retention, by ~2.5-fold. T98G 
cells exhibit a slight but statistically insignificant increase 
in Rhodamine123 retention (Figure 2B, 2C). These results 
are consistent with our chemosensitization studies, which 
revealed that silencing GLI1 increases TMZ response in 
U87-MG cells to a much greater degree than in T98G cells.
It is also of great importance to consider the impact 
Hh inhibition might have on signaling pathways with well-
established significance in TMZ resistance. Both wild-type 
and mutant p53 have been implicated in the progression 
and therapeutic response of GBM tumors. Wild-type p53 
is well known to mediate apoptosis, cell cycle arrest, 
and senescence in response to genotoxic stress through a 
complex tumor suppressive signaling network. Despite the 
presence of altered p53 in 25–30% of primary GBM cases 
[28], much remains unknown regarding the phenotypic 
consequences of p53 mutants on GBM progression. 
Previous research has identified a GLI1-p53 negative 
feedback loop present in neural stem cells and brain tumor 
cells, where GLI1 knockdown was found to increase both 
p53 and active phospho-serine15 p53 in U87-MG cells 
[48]. However, additional signaling mechanisms also 
regulate the inverse relationship between GLI1 and p53. 
Upstream of GLI1, constitutively activated Smoothened 
mutants upregulate MDM2, which then represses p53 
tumor suppression activity [49]. A Hh-p53 negative 
regulatory loop is further maintained due to competitive 
GLI1 and p53 binding to the coactivator TATA Binding 
Protein Associated Factor 9 (TAF9) [50] and Nanog-
mediated upregulation of GLI1 and downregulation of 
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p53 [51]. Consistent with these prior findings, we have 
demonstrated that pharmacological GLI inhibition can 
increase p53 expression U87-MG cells. However, we also 
report the surprising result that this relationship is not 
conserved in T98G cells (Figure 3A–3C). 
Because Hh pathway suppression increased wt-
p53 in U87-MG cells and decreased mut-p53 in T98G 
cells, we hypothesized that silencing GLI1 might induce 
apoptosis in GBM cells, even in the absence of TMZ 
co-treatment. To test this, we assessed the expression of 
proteins downstream of p53 known to mediate apoptosis. 
Surprisingly, we did not find increased expression of 
proteins involved in p53-mediated apoptosis (Figure 4A), 
nor did we observe significant increases in AnnexinV-
FITC/PI staining with GLI1 silencing (Figure 4B). This 
unexpected result led us to consider senescence as an 
alternative explanation for the observed decreases in 
proliferation and metabolic activity with siGLI1 alone. 
Interestingly, we did find that silencing GLI1 induced a 
senescent phenotype in U87-MG cells but not in T98G 
(Figure 5A). While silencing GLI1 and GLI2 has recently 
been demonstrated to induce senescence to restore 
chemosensitivity in melanoma cells [52], Hh signaling 
has not yet been linked to senescence in GBM. Thus, 
our results provide novel insight into Hh signaling as a 
means of evading senescence in GBM cells. Further, 
previous research has identified that loss of PTEN 
can induce premature senescence, which may have a 
compensatory role for apoptosis in this context [41]. Here, 
we demonstrate that while siGLI1 induces senescence, 
expressing PTEN simultaneously with GLI1 silencing 
can prevent this phenotype (Figure 5B). While p53 and 
loss of PTEN have both been implicated in glioma cell 
senescence, we report the novel finding that senescence 
can also be induced by Hh pathway suppression in the 
absence of PTEN. While much remains unknown about 
the role of senescence in tumor progression, senescence 
is thought to suppress tumor growth in that senescent 
cells no longer exhibit limitless replicative potential [53]. 
However, senescent cells that have incurred DNA damage 
also acquire a senescence-associated secretory phenotype 
(SASP), in which senescent cells secrete pro-inflammatory 
factors that can promote tumor progression [54]; this 
warrants future research on the effects of siGLI1-induced 
SASP on GBM progression. 
Also heavily implicated in TMZ resistance, 
MGMT is a DNA repair enzyme that removes alkyl 
groups transferred to the O6 position of guanine by TMZ 
to oppose drug toxicity. Though MGMT expression is 
primarily regulated epigenetically [8], a GLI1-binding 
domain has been identified within the MGMT promoter in 
medulloblastoma [32], and Hh inhibition has been linked 
to MGMT downregulation in GBM cell lines [27, 43]. 
Further, additional reports have sought to relate MGMT 
expression to TMZ treatment [7, 44, 55], though no 
consensus has been reached on whether TMZ modulates 
MGMT expression. For example, one study reported 
that exposing GBM cell lines to TMZ in a cyclic manner 
(3 days of treatment followed by 3 days without drug, 
repeated twice) resulted in MGMT protein upregulation 
in SF268 GBM and SK-N-SH neuroblastoma cell lines 
[7]. Another recent report demonstrated that MGMT 
protein levels are not altered following 72 hours of 10 
µM TMZ exposure in T98G GBM cells [44]. In the 
present study, we observed a dose-dependent decrease 
in MGMT expression by T98G cells following treatment 
with 250–500 µM TMZ for 48 hours (Figure 3D). There 
are numerous possible explanations for this discrepancy, 
as MGMT is regulated by several factors, including 
mutant p53 [9], MEK-ERK [56], mTOR [44], hypoxia 
[15, 57], and microRNAs [58, 59]. Further, the TMZ dose-
dependent MGMT decrease we observed is enhanced 
with GLI1 silencing (Figure 3D). Our data indicate that 
TMZ treatment and GLI1 silencing cooperatively deplete 
MGMT expression, which is consistent with previous 
reports [27, 43]. Our studies, along with previous research, 
highlight the importance of investigating combination 
therapies in multiple GBM models to better understand 
differential response to treatment and predict efficacious 
therapy combinations.
Having established that Hh inhibition induces 
senescence in a loss of PTEN-dependent manner as a 
standalone therapy, we were interested in the fate of GBM 
neurospheres co-treated with Hh inhibitors and TMZ. Our 
studies revealed that pharmacological Hh inhibition with 
GANT61 in combination with TMZ can induce apoptosis 
in U87-MG neurospheres, which consequently reduces 
both neurosphere size and the number of neurospheres 
formed (Figure 6A–6D, Supplementary Figures 5–7). 
Interestingly, our studies reveal that while TMZ as a 
monotherapy reduces the number of large spheres (imaged 
area >1 × 105 µm2) with no significant change in the 
total number of spheres, the addition of GANT61 does 
significantly reduce the sphere count. This is supported 
by previous work, which shows that pharmacological 
or genetic Hh pathway suppression, but not TMZ alone, 
can prevent GSC tumorigenicity in mice [23], and Hh 
and Notch pathway inhibition enhances TMZ sensitivity 
in CD133+ stem-like cells [18]. Our results demonstrate 
that GANT61/TMZ co-treatment suppresses the growth 
of anchorage-independent U87-MG cells thought to be 
more representative of a GSC-rich subpopulation. Taken 
together with our previous results, this suggests that 
senescence mediated by siGLI1 monotherapy is indeed 
tumor suppressive and potentiates the effects of TMZ 
chemotherapy.
Our studies indicate that Hh pathway suppression 
may enhance the cytotoxic effects of TMZ against GBM, 
particularly those expressing low levels of MGMT 
and wild-type p53. We demonstrated that Hh inhibition 
reduces multidrug efflux activity, modulates p53 and 
MGMT expression, induces senescence dependent on 
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the absence of PTEN, and reduces the growth of glioma 
cells exhibiting a stem-like phenotype. Overall, our data 
highlight the importance of investigating how Hh-targeted 
therapies interact with pathways that promote cellular 
resistance mechanisms to ultimately achieve maximal 
tumor reduction and prevent recurrence.
MATERIALS AND METHODS
Cell culture and transient transfections
U87-MG and T98G cells were purchased from 
American Type Culture Collection (ATCC, Manassas, 
VA) and cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum 
(FBS). Cells were maintained in a humidified incubator 
at 37° C, 5% CO2. RNA interference was performed using 
Dharmafect 1 (Dharmacon, Lafayette, CO) according to 
the manufacturer’s protocol to deliver 100 nM siRNA 
(Integrated DNA Technologies, Coralville, IA) to cells 
at approximately 50–60% confluence. Four hours post-
transfection, media containing transfection reagents 
was removed and replaced with fresh media, and cells 
were incubated at 37° C, 5% CO2 for 72 hours prior to 
continued experimentation. siRNA sequences used in this 
study are as follows (written 5ʹ to 3ʹ): siGLI1 sense: CCA 
GGA AUU UGA CUC CCA ATT, siGLI1 antisense: UUG 
GGA GUC AAA UUC CUG GCT, siScramble (siScr) 
sense: GUG CAC CAA CGA CUU AUC ATT, siScr 
antisense: UGA UAA GUC GUU GGU GCA CT. Plasmid 
DNA transfections were performed using Mirus TransIT 
X2 (Mirus Bio LLC, Madison, WI) to deliver 25 ng/mL 
pcDNA3-FLAG PTEN (Addgene #78777) or pcDNA3-
FLAG HA (Addgene #10792) to cells at approximately 
80% confluence. Twenty-four hours post-transfection, 
media containing transfection reagents was removed and 
replaced with fresh media, and cells were incubated at 
37° C, 5% CO2 for 48 hours prior to analysis.
Immunofluorescent staining and image analysis
Cells were seeded on coverslips in 24-well plates 
and grown overnight prior to treatment with either Hh 
activating agents or Hh inhibitors. For Hh activation 
experiments, cells were treated with recombinant human 
sonic hedgehog (rhShh) (R&D Systems, Minneapolis, 
MN) at 25 ng/ml to induce Hedgehog signaling and were 
incubated 48 hours at 37° C, 5% CO2. For chemical Hh 
inhibition experiments, cells were treated with 10 µM 
GANT61 (Cayman Chemical Company, Ann Arbor, 
MI) and were incubated 48 hours at 37° C, 5% CO2. 
Subsequently, coverslips were washed in phosphate 
buffered saline (PBS), fixed in ice-cold acetone (for GLI1 
staining) or 4% formaldehyde (for p53 staining), and 
blocked in PBS containing 1% bovine serum albumin 
(BSA), 0.2% cold-fish gelatin, and 0.1% Tween-20 
for 1 hour at room temperature. Coverslips were then 
probed with antibodies under the following conditions: 
1:500 rabbit anti-GLI1 (Proteintech, Rosemont, IL) or 
1:500 mouse anti-p53 (Santa Cruz Biotechnology, Santa 
Cruz, CA) diluted in blocking buffer at 4° C overnight, 
followed by incubation with AlexaFluor 488-conjugated 
secondary antibodies diluted in blocking buffer (1:1000, 
ThermoFisher Scientific, Waltham, MA) for 1 hour at 
room temperature. Cells were rinsed in PBS supplemented 
with 0.1% Tween-20, counterstained with 4’,6-diamidino-
2-phenylindole (DAPI) to identify nuclei and phalloidin 
to identify actin cytoskeleton (Cell Signaling Technology, 
Danvers, MA), mounted on slides using gelvatol, and 
imaged on a Zeiss AxioObserver.Z1 microscope (Zeiss, 
Thornwood, NY). For each condition, 25 images were 
acquired from the central region of the coverslip using 
automated X, Y, and focus positioning.
Each image set was checked by a masked observer 
for out of focus images, which were discarded from 
analysis, resulting in sets of 22–25 images encompassing a 
minimum of 1000 cells per set. Each image was analyzed 
using a custom image analysis script in MATLAB 
(2016a; Mathworks, Natick, MA). Briefly, the image 
was segmented into nuclear and cytoplasmic regions and 
mean staining intensity was determined for each region. 
To identify the nuclear compartment, the DAPI stain was 
normalized and thresholded. To identify the cytoplasmic 
compartment, the phalloidin stain was normalized, 
morphologically closed with a 6 µm disk element, and 
thresholded. The thresholded stains were used as masks to 
determine the mean intensity of GLI1 and p53 staining in 
the two components. Data was analyzed frame by frame 
and averaged within each set.
Western blotting
Protein samples were prepared by lysing cells in 
radioimmunoprecipitation assay (RIPA) buffer (Amresco, 
Solon, OH) supplemented with 2X Halt Protease and 
Phosphatase Inhibitor Cocktail (ThermoFisher Scientific, 
Waltham, MA) on ice. Sample protein concentration was 
measured using a detergent-compatible modified Lowry 
assay (Bio-Rad, Hercules, CA) relative to a BSA standard. 
Lysate was denatured in Laemmli buffer (Amresco, Solon, 
OH) at 99° C for 20 minutes, and 30 µg protein was loaded 
per well in a Bolt® 4–12% Bis-Tris gel (ThermoFisher 
Scientific, Waltham, MA) and separated by electrophoresis 
at 135V for 1 hour. Protein was transferred to a 0.45 µm 
nitrocellulose membrane, which was subsequently blocked 
in 5% nonfat milk in tris-buffered saline containing 0.1% 
Tween-20 (TBST). Membranes were probed with primary 
antibodies at 4° C overnight, followed by incubation with 
anti-rabbit (1:25000) or anti-mouse (1:25000) horseradish 
peroxidase-conjugated secondary antibodies (Kirkegaard 
& Perry Laboratories, Inc., Gaithersburg, MD) for 1 hour 
at room temperature. Primary antibodies were obtained 
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from Cell Signaling Technology (Danvers, MA) (MGMT, 
α-tubulin, β-actin) or Santa Cruz Biotechnology (Rb, 
p21, PTEN, PUMA, Bid, MDM2). Protein bands were 
detected by chemiluminescence using VisiGlo™ Select 
Chemiluminescent Substrate (Amresco, Solon, OH) and 
imaged on a ChemiDoc-It2 Imager (UVP, Upland, CA).
Senescence analysis
Cells were seeded in 24-well plates at a density 
of 25,000 cells/well and cultured overnight prior 
to transfection with siGLI1 or pPTEN (or relevant 
controls). Cellular senescence was analyzed using a 
Senescence Associated β-Galactosidase (SAβGal) kit 
(Cell Signaling Technology, Danvers, MA) according to 
the manufacturer’s protocol. Stained cells were imaged 
using a Zeiss Axioobserver.Z1 microscope equipped 
with a color camera. For each condition, 25 images were 
acquired from the central region of the well plate using 
automated X, Y, and focus positioning. SAβGal staining 
was quantified using a custom MATLAB script. Briefly, 
cells were segmented from brightfield images using the 
Sobel method. RGB images were converted to HSV 
colorspace, and positive SAβGal staining regions within 
cells were thresholded using hue values from 0.265–0.58. 
The total area of SAβGal-positive regions was divided by 
the total area occupied by cells to obtain the fraction of 
SAβGal-positive area for each condition.
Dose response, viability assay, and synergy 
assessment
GBM cytoxicity induced by temozolomide (TMZ, 
reconstituted in DMSO; Sigma-Aldrich, St. Louis, MO) 
chemotherapy was investigated following Hedgehog 
inhibition by silencing GLI1. Cells were seeded in 
96-well plates at 5000 cells/well and transfected with 
siGLI1 (or siScr) as described above. Subsequently, 
cells were treated with increasing TMZ dosages (0–1500 
µM) for 48 hours, and viability was assessed using an 
AlamarBlue assay (ThermoFisher Scientific, Waltham, 
MA) according to the manufacturer’s protocol with a 
2-hour AlamarBlue incubation. Fluorescence intensity 
(Ex 550 nm/Em 585 nm) was recorded using a Synergy 
H1 Plate Reader (BioTek, Winooski, VT). Cells 
transfected with siScr and receiving no TMZ were taken 
to exhibit 100% metabolic activity, and cells treated with 
DMSO equivolume to the highest TMZ dosage diluted 
in media were used to verify that toxicity was due to 
TMZ treatment rather than DMSO-induced membrane 
permeabilization, since TMZ was reconstituted in DMSO 
prior to dilution in media.
Therapeutic synergy between GLI1 silencing and 
TMZ was assessed using previously reported methods 
[60]. For each group co-treated with siGLI1 and TMZ, a 
projected additive effect was calculated by multiplying the 
fraction of metabolic activity reduced by GLI1 silencing 
alone by the fraction of metabolic activity reduced by 
each TMZ dose. Then, the observed metabolic activities 
with co-treatment were compared to the projected values 
by one-way ANOVA with post-hoc Tukey. Co-treatments 
producing metabolic activities statistically greater than the 
projected value were taken to be antagonistic, statistically 
insignificant from the projected value were taken to be 
additive, and statistically lower than the projected value 
were taken to be synergistic.
Assessment of drug efflux transporter activity
Rhodamine123 (Sigma-Aldrich, St. Louis, MO) 
efflux was measured to evaluate the impact of Hh/
GLI1 inhibition on multidrug resistance (MDR) efflux 
transporter activity because it is a known substrate for 
membrane efflux transporters and its fluorescence is 
easily detectable [39, 60]. Cells were seeded in 24-well 
plates and grown overnight, then transfected with siGLI1 
or siScr as described previously. Transfected cells were 
subsequently incubated with 5 µM Rhodamine123 for 
20 minutes at 37° C, 5% CO2, then the Rhodamine123-
containing medium was removed, cells were replenished 
with fresh media and incubated for another 20 minutes 
at 37° C, 5% CO2 to allow for efflux. Treated cells were 
harvested by trypsinization, fixed in 4% formaldehyde, 
resuspended in PBS and analyzed for Rhodamine123 
fluorescence (Ex 488 nm/Em 533/30 nm) by flow 
cytometry using a BD AccuriTM C6 cytometer (Becton 
Dickinson Biosciences, Franklin Lakes, NJ).
Proliferation assay
Cellular proliferation following Hedgehog inhibition 
by GLI1 silencing was evaluated using a Click-iT® EdU 
Proliferation Assay (ThermoFisher Scientific, Waltham, 
MA). Cells seeded in 24-wells were transfected with 
siRNA as described previously and then incubated with 10 
µM EdU for 16 hours at 37° C, 5% CO2. Cells were then 
harvested by trypsinization, washed in 1% BSA in PBS, 
fixed in 4% formaldehyde, permeabilized with 0.05% 
saponin, and stained according to the manufacturer’s 
protocol. EdU incorporation was measured by flow 
cytometry (Ex 488 nm/Em 533/30 nm) using a BD 
AccuriTM C6 cytometer (Becton Dickinson Biosciences, 
Franklin Lakes, NJ).
Neurosphere growth and apoptosis analysis
Neurospheres were grown from a single-
cell suspension of U87-MG’s in NeuroCult NS-A 
(STEMCELL Technologies, Vancouver, BC, Canada) 
medium supplemented with recombinant human epidermal 
growth factor (EGF, 20 ng/mL), recombinant human basic 
fibroblast growth factor (bFGF, 10 ng/mL), and heparin 
sulfate (2 µg/mL). Cells were plated in ultra-low adhesion 
24-well plates at a density of 10,000 cells/mL for growth 
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analysis in medium containing 10 µM TMZ and 10, 15, or 
20 µM GANT61 for one week at 37° C, 5% CO2. Controls 
contained DMSO and/or ethanol (which are used to 
reconstitute TMZ and GANT61, respectively) at volumes 
equivalent to the highest TMZ and/or GANT61 doses used 
in the experiment. After one week, neurospheres were 
imaged for size and sphere forming efficiency analysis. 
Imaging was conducted on a Zeiss AxioObserver.Z1 
microscope using automated stage control to image 
each well in its entirety. Following acquisition, images 
were stitched using Zeiss Efficient Navigation software 
(ZEN 2.0; Zeiss) and exported as single field images on 
the OME-TIFF standard and analyzed using a custom 
MATLAB script. Briefly, the well exterior was discarded 
by mapping an active contour to the high gradient region 
at the well edge [61]. After discarding the well exterior, 
varying background illumination was corrected using 
morphological reconstruction-based top-hat and bottom-
hat filters [62] followed by homomorphic filtering. Image 
contrast was globally enhanced using homomorphic 
filtering and phase-preserving dynamic range compression 
and locally enhanced using the CLAHE algorithm 
[63, 64]. Following enhancement, spheres were identified 
as increases in local image entropy and touching spheres 
were separated using watershed-based segmentation. 
Automated sphere identification was manually confirmed 
for each image analyzed. Sphere growth data were 
reported as the average number of spheres per treatment 
group across 9 independent replicates, where spheres 
were defined as objects with diameter greater than 50 
µm and eccentricity less than 0.8, and as size (sphere 
projected area) distributions for each treatment group. To 
evaluate apoptosis in U87-MG neurospheres treated with 
TMZ ± GANT61, neurospheres grown from a single-cell 
suspension at a density of 25,000 cells/mL were harvested 
after 6 days growth in NeuroCult NS-A medium ± 50 
µM TMZ ± 0- 15 µM GANT61, trypsinized to a single-
cell suspension, and analyzed using an AnnexinV-FITC/
propidium iodide (PI) staining kit (Cayman Chemical 
Company, Ann Arbor, MI) according to the manufacturer’s 
protocol. Fluorescence intensity was measured by flow 
cytometry analysis using a BD Accuri™ C6 cytometer, 
with Annexin V-FITC recorded using Ex 488 nm/Em 
533/30 nm (FL-1) and PI recorded using Ex 488nm/Em 
670LP (FL-3). Measurements were appropriately corrected 
for spillover using standard color correction procedures.
Quantitative real-time polymerase chain reaction 
(qPCR)
qPCR was used to confirm that U87-MG 
neurospheres exhibit a stem-like phenotype relative to 
adherent cultures. Cells were grown as neurospheres 
as described previously for one week, then mRNA 
was isolated using an Isolate II RNA Mini Kit (Bioline, 
Taunton, MA). The relative expression of CD133, Nanog, 
and Sox2 were measured using SensiFAST™ SYBR® One-
Step master mix and normalized to that of GAPDH. qPCR 
was performed on a LightCycler® 96 (Roche Diagnostics 
Corporation, Indianapolis, IN). Primer sequences were 
as follows: CD133 F - GGACCCATTGGCATTCTC, 
CD133 R - CAGGACACAGCATAGAATAATC, Nanog 
F – AAATTGGTGATGAAGATGTATTCG, Nanog R – GC
AAAACAGAGCCAAAAACG, Sox2 F – AACATGA
TGGAGACGGTGCTGAA, Sox2 R – CAGCCGTTC
ATGTGCGCGTA. Gene expression in cells grown as 
neurospheres was compared to that of cells grown in 
adherent conditions.
Statistical analysis
Differences between two groups were assessed for 
statistical significance by Student’s t-test for each cell line 
independently. TMZ dose response data and sphere growth 
data were analyzed using a one-way analysis of variance 
(ANOVA) with post-hoc Tukey test using MATLAB 
software (MathWorks, Natick, MA). Neurosphere 
apoptosis data were analyzed using one-way ANOVA with 
post-hoc Fisher’s least significant difference test. Flow 
cytometry data was analyzed using either FlowJo software 
(Tree Star Inc, Ashland, OR) or CFlow software (Becton 
Dickinson Biosciences, Franklin Lakes, NJ). Differences 
were considered statistically significant at p < 0.05. Data 
shown represents the mean ± standard deviation of three 
independent experimental replicates.
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